Chronic migraine affects roughly 2% of the global population, with patients experiencing 15 or more headache days per month. For those who have exhausted conventional treatments — triptans, CGRP inhibitors, beta-blockers, and Botox — ketamine tablets represent an emerging option that some pain specialists are beginning to explore.
What Makes Chronic Migraine So Difficult to Treat
Chronic migraine is not simply a series of bad headaches. It involves central sensitization, where the brain's pain-processing pathways become hyperexcitable over time. This neuroplastic shift means the nervous system essentially "learns" to amplify pain signals, making each successive episode easier to trigger.
Standard preventive medications work through various mechanisms — blocking CGRP receptors, modulating serotonin, or reducing neuronal excitability — but a significant subset of patients (estimated at 30–40%) do not achieve adequate relief. These treatment-resistant cases are where ketamine's unique pharmacology becomes relevant.
How Ketamine May Help Migraines
Ketamine works primarily as an NMDA receptor antagonist. NMDA receptors play a central role in:
- Central sensitization — the process that makes chronic migraine self-perpetuating
- Cortical spreading depression — the wave of neuronal activity believed to underlie migraine aura
- Wind-up pain — the progressive amplification of pain signals in the trigeminal system
By blocking NMDA receptors, ketamine may interrupt these pathological processes at a fundamental level. This is a different mechanism than any currently approved migraine medication, which is why researchers and clinicians have shown growing interest.
The Glutamate Connection
Migraine research has increasingly focused on glutamate, the brain's primary excitatory neurotransmitter. Elevated glutamate levels have been found in the cerebrospinal fluid of chronic migraine patients. Since ketamine directly modulates glutamate signaling through NMDA receptor blockade, it targets what may be a core driver of migraine chronification.
Evidence for Oral Ketamine in Migraine
Most published research on ketamine for migraine has used intravenous infusions. However, oral ketamine tablets are gaining attention as a more practical alternative for ongoing management.
Key Findings
A 2022 retrospective study published in Regional Anesthesia & Pain Medicine examined patients with refractory chronic migraine who received low-dose oral ketamine. The study reported that approximately 50% of patients experienced a meaningful reduction in headache frequency and severity over a 3-month period.
Smaller case series have reported:
- Reduction in monthly migraine days from an average of 20+ to <12 in responders
- Decreased reliance on acute rescue medications
- Improved functional capacity and quality of life scores
It is important to note that large-scale randomized controlled trials specific to oral ketamine tablets for migraine have not yet been completed. Current evidence, while promising, remains preliminary.
How Tablets Compare to IV for Migraine
IV ketamine infusions for migraine typically involve multi-day hospital or clinic-based protocols. Oral ketamine tablets offer several practical advantages:
- Home administration after initial stabilization
- Lower peak plasma levels, which may reduce dissociative side effects
- Sustained low-level exposure that may help maintain NMDA receptor modulation
The trade-off is lower bioavailability — typically 20–25% for oral tablets compared to nearly 100% for IV. Providers account for this when determining appropriate doses.
Typical Dosing Approaches
There is no standardized protocol for oral ketamine tablets in migraine. However, clinicians experienced with this approach generally follow these patterns:
Starting Doses
Most providers begin conservatively, often at 25–50 mg taken once or twice daily. This allows assessment of tolerability before any upward adjustment.
Maintenance Dosing
Patients who respond may be maintained on doses ranging from 50–200 mg daily, often divided into two or three doses. The goal is to find the minimum effective dose that provides meaningful migraine reduction without problematic side effects.
For more on general dosing principles, see our dosing guide.
Rescue Use vs. Preventive Use
Some providers prescribe oral ketamine tablets as a rescue medication for severe migraine attacks that do not respond to first-line treatments. Others use a daily preventive approach. A small number combine both strategies — a lower daily preventive dose with the option for a slightly higher dose during acute attacks.
Side Effects and Safety Considerations
The side effects of oral ketamine tablets are dose-dependent and generally manageable at the doses used for migraine. Common effects include:
- Dizziness and lightheadedness — most common, typically mild
- Nausea — can be addressed with timing adjustments or anti-nausea medication
- Dissociation — usually mild at low doses; patients often describe feeling "slightly detached"
- Fatigue or drowsiness — especially in the first 1–2 hours after dosing
Patients should not drive or operate heavy machinery after taking ketamine tablets. Review our guide on driving considerations for more details.
Long-Term Safety
Chronic use of ketamine raises questions about urological and hepatic health. At the low doses typically used for migraine (well below recreational levels), these risks appear minimal but require monitoring. Regular check-ups including liver function tests and urinary symptom assessment are standard practice. Our article on long-term outcomes covers this in more depth.
Who Might Be a Candidate
Oral ketamine tablets for migraine are generally considered for patients who:
- Have been diagnosed with chronic migraine (15+ headache days per month for >3 months)
- Have tried and failed at least 2–3 standard preventive medications
- Have tried and failed or are not candidates for CGRP-targeting therapies
- Do not have a history of psychosis, active substance use disorder, or uncontrolled hypertension
- Are willing to comply with monitoring requirements
How to Discuss This With Your Provider
If you are considering ketamine tablets for chronic migraine, come prepared:
- Document your treatment history — list all preventive and acute medications you have tried, with approximate dates and reasons for discontinuation
- Track your headache days — a migraine diary showing frequency, severity, and medication use is invaluable
- Ask about experience — inquire whether your provider has prescribed ketamine for headache conditions before, or whether a referral to a headache specialist with ketamine experience would be appropriate
- Discuss monitoring plans — understand what lab work and follow-up visits will be required
For guidance on finding providers who prescribe oral ketamine, see our finding prescribers page.
What Patients Report
Anecdotally, patients who respond to oral ketamine for migraine often describe a gradual reduction in both the frequency and intensity of attacks over the first 4–8 weeks. Some report that their migraines become more responsive to standard acute treatments (triptans, NSAIDs) even when ketamine does not eliminate attacks entirely.
Not everyone responds. Estimates suggest that roughly half of treatment-resistant migraine patients may see meaningful benefit from ketamine, while the other half may not experience significant improvement.
The Bottom Line
Ketamine tablets are not a first-line migraine treatment, and they are not FDA-approved for this indication. However, for patients with chronic migraine who have not found relief through standard approaches, they represent a pharmacologically distinct option worth discussing with a knowledgeable provider. The evidence base is growing, and ongoing research may help clarify which patients are most likely to benefit.
References
- Glutamate and Migraine: A Review — Comprehensive review of glutamate's role in migraine pathophysiology (Headache, 2019)
- Ketamine for Refractory Headache: A Retrospective Analysis — Retrospective study examining ketamine use in treatment-resistant headache disorders (Regional Anesthesia & Pain Medicine, 2022)
- NMDA Receptor Antagonists and Migraine — NIH-indexed review of NMDA receptor modulation in migraine treatment
- Chronic Migraine: Epidemiology and Disease Burden — WHO-referenced data on global migraine prevalence and treatment gaps
- Central Sensitization in Chronic Pain — Mayo Clinic overview of migraine mechanisms and treatment approaches
Share